logo-loader
viewScancell Holdings PLC

Scancell Holdings appoints new independent director

Dr Ursula Ney joins the immunotherapies specialist with immediate effect, replacing Dr Matthew Frohn who stands down from end October

Scancell Holdings PLC -
Ney was a director at UK biotech pioneers Celltech and Antisoma and spent her early career with Sandoz and Roche

Scancell Holdings PLC (LON:SCLP) has appointed a new independent director with 30 years’ experience in the life sciences sector.

Dr Ursula Ney joins the immunotherapies specialist with immediate effect, replacing Dr Matthew Frohn, who is standing down at the end of the month.

Ney was a director at UK biotech pioneers Celltech and Antisoma and spent her early career with Sandoz and Roche.

Most recently, she was chief executive of French drug developer Genkyotex and is currently a non-executive director of Proteome Sciences.

“Ursula’s extensive late-stage development experience in the biotech sector will be invaluable as the company continues to develop its product pipeline,” said Scancell chairman, Dr John Chiplin.

“I’d also like to take this opportunity to thank Matthew Frohn for the invaluable contributions he has made to the company since he was first appointed to the Board in 2006. We wish him well in his future endeavours.”

Quick facts: Scancell Holdings PLC

Price: 5.375 GBX

LSE:SCLP
Market: LSE
Market Cap: £25.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read